131I-apamistamab + fludarabine

**131I-apamistamab + fludarabine** is a combination regimen used as a conditioning therapy prior to allogeneic hematopoietic stem cell transplantation (HSCT) in patients with relapsed or refractory acute myeloid leukemia (AML)[1][2][4][5]. 131I-apamistamab is a radioimmunoconjugate that targets the CD45 antigen on leukocytes, delivering cytotoxic radiation specifically to hematopoietic cells. Fludarabine is a purine analog chemotherapeutic that inhibits DNA synthesis, contributing immunosuppression and cytoreduction. This combination is frequently used with low-dose total body irradiation (TBI) to enhance marrow ablation and disease control, with the ultimate goal of improving transplant success and preventing leukemia recurrence[1][2][4]. The regimen is designed to be an alternative to standard myeloablative conditioning, especially for patients unsuitable for intensive regimens, and is under evaluation in Phase 2/3 clinical trials. Developer: Actinium Pharmaceuticals[1][2][4]. Fludarabine is an established generic chemotherapy agent.

Other names

131I-apamistamabfludarabine131I-apamistamab + fludarabine